Trial Profile
A Phase 2, Open-Label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2015
Price :
$35
*
At a glance
- Drugs Motesanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 29 Sep 2006 Status change
- 11 Nov 2005 New trial record.